3 year follow up of ZUMA-12: CAR T-cell as a first line treatment in patients with high-risk LBCL

The ZUMA-12 study represents a phase 2 clinical trial aimed at investigating the efficacy of Axi-Cel as a primary therapeutic intervention for individuals diagnosed with high-risk LBCL. High-risk categorization involved the assessment of MYC and BCL2 and/or BCL6 rearrangements or an IPI score of ≥3, coupled with a positive PET scan following two cycles of chemotherapy.

This presentation highlights outcomes observed three years after the initial findings, revealing sustained advantages associated with the early implementation of Axi-Cel. Following a treatment duration exceeding 40 months, the evaluation of 37 patients demonstrated a notable overall response rate (OR) exceeding 90%. The PFS and OS rates among these patients, as determined at the three-year mark, stood at 75% and 81%, respectively. AE was universally reported among all patients, exhibiting a profile consistent with that observed during the primary analysis.

In light of these observations, we deduce a heightened efficacy of CAR T-cell therapy in high-risk LBCL patients. This substantiates the rationale for initiating frontline investigations comparing this innovative approach against the current standard of care involving first-line chemoimmunotherapy.

Reference:

Chavez JC et al. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). ASH 2023, Oral and poster abstracts 894

With the educational support of: